5-fluoro-2′,5′-di-O-trityl-uridine | 61079-69-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: 5-fluoro-2′,5′-di-O-trityl-uridine
• 英文别名: 5’,2’-bis-O-trityl-5-fluorouridine；5-fluoro-1-[(2R,3R,4R,5R)-4-hydroxy-3-trityloxy-5-(trityloxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
• CAS: 61079-69-4
• 化学式: C₄₇H₃₉FN₂O₆
• 分子量: 746.835
• InChiKey: OEQONNLGPXUGRH-VLGKNGBSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.9
• 重原子数：
  56
• 可旋转键数：
  12
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  97.3
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  5-氟尿嘧啶核苷 、 三苯基氯甲烷 在 吡啶 作用下， 反应 18.0h， 以10 mg的产率得到5-fluoro-3′,5′-di-O-trityl-uridine
  参考文献：
  名称：

  寻找黄病毒抑制剂的第2部分：三甲基化，二苯基甲基化和其他烷基化的核苷类似物

  摘要：

  几种黄病毒，例如黄热病病毒和登革热病毒，会在人体内引起严重的致命感染。继我们最初的命中3'，5'-双歧化尿苷1之后，合成了一系列烷基化核苷类似物，并评估了它们对登革热病毒和黄热病病毒的体外抗病毒活性。迄今为止，烷基和芳基连接在糖环的各个位置，并带有杂环碱基的细微变化。在新的衍生物系列中，3'，5'- di- O-三苯甲基-5-氟-2'-脱氧尿苷（39）是该系列中最有效的衍生物，可抑制黄热病病毒和登革热病毒的复制，其50有效浓度百分比（EC 50）〜1μg/ mL，无明显细胞毒性。其他氟化衍生物被证明更具毒性。几乎所有具有3'，5'-二-O-苯甲酰基-2'-脱氧尿苷（50）的二苯基甲基化嘧啶核苷都具有很强的低至1μg/ mL的细胞毒性作用。

  DOI：

  10.1016/j.ejmech.2014.02.011

文献信息

• Anti-flavivirus Activity of Different Tritylated Pyrimidine and Purine Nucleoside Analogues
  作者：Christopher McGuigan、Michaela Serpi、Magdalena Slusarczyk、Valentina Ferrari、Fabrizio Pertusati、Silvia Meneghesso、Marco Derudas、Laura Farleigh、Paola Zanetta、Joachim Bugert

  DOI：10.1002/open.201500216

  日期：2016.6

  A series of tritylated and dimethoxytritylated analogues of selected pyrimidine and purine nucleosides were synthesized and evaluated for their in vitro inhibitory activity against two important members of the genus Flavivirus in the Flaviviridae family, the yellow fever (YFV) and dengue viruses (DENV). Among all compounds tested, the 5′‐O‐tritylated and the 5′‐O‐dimethoxytritylated 5‐fluorouridine

  合成了一系列选定的嘧啶和嘌呤核苷的三苯甲基化和二甲氧基三苯甲基化的类似物，并评估了它们对黄病毒科中黄病毒属的两个重要成员黄热病和登革热病毒的体外抑制活性。在所有测试的化合物中，5'-O-三苯甲基化和5'-O-二甲氧基三苯甲基化的5-氟尿苷衍生物均具有抗YFV的能力。有趣的是，在嘌呤类似物系列中，5'O，N-双三苯甲基化的氟达拉滨衍生物在μm浓度下表现出对DENV的强抑制活性，但对YFV的效力却明显减弱。
• Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation
  申请人：Gilead Pharmasset LLC

  公开号：US10100076B2

  公开（公告）日：2018-10-16

  The disclosed invention is a composition for and a method of seating a Flaviviridae (including BVDV and HCV), Orthomyxoviridae (including Influenza A and B) or Paramyxoviridae (including RSV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans, using a nucleoside of general formula (I)-(XXIII) or its pharmaceutically acceptable salt or prodrug. This invention also provides an effective process to quantify the viral load, and in particular BVDV, HCV or West Nile Virus load, in a host, using real-time polymerase chain reaction (“RT-PCR”). Additionally, the invention discloses probe molecules that can fluoresce proportionally to the amount of virus present in a sample.

  所述的发明是关于一种用于在宿主中（包括动物，特别是人类）使用一般式（I）-（XXIII）的核苷或其药用可接受的盐或前药，对Flaviviridae（包括BVDV和HCV）、Orthomyxoviridae（包括流感A和B）或Paramyxoviridae（包括RSV）感染，或与异常细胞增殖相关的疾病进行座位的组合物和方法。该发明还提供了一种有效的过程，用于使用实时聚合酶链反应（“RT-PCR”）在宿主中定量病毒载量，特别是BVDV、HCV或西尼罗河病毒载量。此外，该发明还揭示了可以与样本中存在的病毒量成比例发出荧光的探针分子。
• MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION
  申请人：GILEAD SCIENCES, INC.

  公开号：US20140057863A1

  公开（公告）日：2014-02-27

  The disclosed invention is a composition for and a method of treating a Flaviviridae (including BVDV and HCV), Orthomyxoviridae (including Influenza A and B) or Paramyxoviridae (including RSV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans, using a nucleoside of general formula (I)-(XXIII) or its pharmaceutically acceptable salt or prodrug. This invention also provides an effective process to quantify the viral load, and in particular BVDV, HCV or West Nile Virus load, in a host, using real-time polymerase chain reaction (“RT-PCR”). Additionally, the invention discloses probe molecules that can fluoresce proportionally to the amount of virus present in a sample.

  本公开发明涉及一种用于治疗Flaviviridae（包括BVDV和HCV）、Orthomyxoviridae（包括甲型和乙型流感病毒）或Paramyxoviridae（包括RSV）感染或与异常细胞增殖相关的条件的组合物和方法，适用于宿主，包括动物，特别是人类，使用一种核苷酸的一般式（I）-（XXIII）或其药学上可接受的盐或前药。本发明还提供了一种有效的过程，用于定量病毒载量，特别是BVDV、HCV或West Nile病毒载量，在宿主中使用实时聚合酶链反应（“RT-PCR”）。此外，本发明还揭示了可以与样品中存在的病毒数量成比例发光的探针分子。
• MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION
  申请人：Pharmasset Limited

  公开号：EP1411954A2

  公开（公告）日：2004-04-28
• [EN] MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION<br/>[FR] NUCLEOSIDES MODIFIES POUR TRAITER DES INFECTIONS VIRALES ET UNE PROLIFERATION CELLULAIRE ANORMALE
  申请人：PHARMASSET LTD

  公开号：WO2002032920A2

  公开（公告）日：2002-04-25

  The disclosed invention is a composition for and a method of treating a Flaviviridae (including BVDV and HCV), Orthomyxoviridae (including Influenza A and B) or Paramyxoviridae (including RSV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans, using a nucleoside of general formula (I)-(XXIII) or its pharmaceutically acceptable salt or prodrug. This invention also provides an effective process to quantify the viral load, and in particular BVDV, HCV or West Nile Virus load, in a host, using real-time polymerase chain reaction ('TR-PCR'). Additionally, the invention discloses probe molecules that can fluoresce proportionally to the amount of virus present in a sample.